You are here: Industry Insights > rituximab

News List

Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH PharmaSources
December 11, 2023
InnoCare Pharma announced today that the latest data from InnoCare's oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
New oral chronic lymphocytic leukaemia treatment made available on NHS europeanpharmaceuticalreview
March 22, 2021
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab pharmaceutical-business-review
September 23, 2020
Janssen Pharmaceutical, part of Johnson & Johnson, has secured approval from the European Commission (EC) for expanded use of Imbruvica (ibrutinib) in combination with rituximab for previously untreated adult patients with chronic lymphocytic leukaemia.
EU expands scope of Imbruvica to include untreated CLL patients pharmatimes
September 17, 2020
The European Commission (EC) has expanded the marketing authorisation for Janssen's Imbruvica (ibrutinib) to include treatment naïve patients with chronic lymphocytic leukaemia (CLL).
Janssen gets CHMP positive opinion for expanded use of IMBRUVICA, rituximab combo in CLL pharmaceutical-business-review
July 29, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for IMBRUVICA ...
FDA Approves IMBRUVICA, Rituximab Combination for Chronic Lymphocytic Leukemia americanpharmaceuticalreview
April 24, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for ...
NICE does not recommend polatuzumab vedotin to treat lymphoma europeanpharmaceuticalreview
March 03, 2020
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
Lenalidomide recommended for use with rituximab by NICE europeanpharmaceuticalreview
March 03, 2020
NICE has given its positive opinion to lenalidomide in combination with rituximab as a ‘chemotherapy-free’ treatment for lymphoma.
Rituximab Noninferior to Cyclosporine in Membranous Nephropathy drugs
July 18, 2019
Rituximab Noninferior to Cyclosporine in Membranous Nephropathy.
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma drugs
May 29, 2019
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma.

Previous page 1 2 3 Next page